

Mainstay Medical Announces Date for Half Year Results

Dublin – Ireland, 25 August 2015 – Mainstay Medical International plc (“**Mainstay**” or the “**Company**” listed on *Euronext Paris: MSTY.PA* and *ESM of the Irish Stock Exchange: MSTY.IE*) announces that it will release 2015 Half Year results on Monday, 31 August, 2015 at 07:00am Dublin time.

The Company will host a live conference call and webcast (in English) for analysts and investors on Monday, 31 August, 2015 at 2:30pm Dublin-London time (3:30pm Paris; 09:30am New York).

Dial in details for this call are outlined below:

Ireland Toll Free Number:	1800 936 842
France Toll Free Number:	0805 101 988
Finland Toll Free Number:	0800 523 133
Netherlands Toll Free Number:	0800 265 8619
USA Toll Free Number:	1866 928 7517
International Non Toll Free Number:	+44 203 139 4830
Passcode:	70678930#

The live webcast will be available on the “Investors” section of Mainstay Medical website at: <http://www.mainstay-medical.com/investors>

During the conference call there will be an opportunity to ask questions. Instructions for this will be provided at the start of the call. Questions for the conference call are welcomed in advance via e-mail to investor-relations@mainstay-medical.com.

- End -

About Mainstay

Mainstay is a medical device company which is developing an innovative implantable neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States and Australia, and is listed on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

About Chronic Low Back Pain

One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the lower back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically

stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on individuals, families, communities, industry, and governments.

Further information can be found at www.mainstay-medical.com.

ReActiv8 is an investigational device and is not approved for commercialisation anywhere in the world.

CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.

Media queries:

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Hendrik Thys, Consilium (International and trade media)
Tel: +44 203 709 5700/+ 44 792 169 7654
Email: Mainstaymedical@consilium-comms.com

Jonathan Neilan, FTI Consulting
Tel: +353 1 663 3686
Email: jonathan.neilan@fticonsulting.com

Astrid Villette, FTI Consulting (French language enquiries)
Tel: +33 1 47 03 69 51
Email: Astrid.Villette@fticonsulting.com

Investor relations:

Jillian Connell, The Trout Group LLC
Tel: +1 646 378 2956 / +1 617 309 8349
Email: jconnell@troutgroup.com

ESM Advisers:

Fergal Meegan or Barry Murphy, Davy
Tel: +353 1 6796363
Email: fergal.meegan@davy.ie or barry.murphy2@davy.ie